{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:48:38Z","timestamp":1776286118977,"version":"3.50.1"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)2 trial builds on the foundational STAMPEDE trial, which introduced innovative multiarm treatment protocols for metastatic prostate cancer. This survey assessed Nigeria's readiness for the STAMPEDE2 trial by evaluating current clinical practices, radiotherapy infrastructure, systemic therapy usage, and imaging capabilities across its six geopolitical zones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We mapped the radiotherapy centers and machines currently available (commissioned) and in the Nigerian pipeline. A structured questionnaire comprising 31 questions in six sections was disseminated to clinical and radiation oncologists via Google Forms. The survey ran from July to September 2024, gathering data on radiotherapy availability, systemic therapies, advanced imaging, and readiness for clinical trial participation. Descriptive statistical analysis was conducted using Microsoft Excel. Responses were aggregated from 14 cancer centers across Nigeria, encompassing both public and private facilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The survey identified 23 operational radiotherapy machines distributed across 12 centers, with 19 additional facilities in the pipeline. These centers were predominantly located in urban areas such as Lagos and Abuja. Prostate cancer treatment modalities are available; however, access to agents such as abiraterone and enzalutamide was reported in 73% of centers. There is one operational positron emission tomography\/computed tomography facility in Nigeria. Clinicians expressed strong interest in participating in trials although some gaps in infrastructure, particularly in rural areas, and limited access to advanced treatments like 177Lu-PSMA-617 were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The findings underscore Nigeria's potential readiness for the STAMPEDE2 trial, other clinical trials, and collaborative research, bolstered by an expanding radiotherapy infrastructure and clinician enthusiasm for advanced therapeutic approaches. Initiatives like the Cancer Health Fund and the National Cancer Access Partnership represent significant steps toward equitable cancer care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00232","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:59:25Z","timestamp":1776283165000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Mapping Radiotherapy Resources for Prostate Cancer Trials in Nigeria: A STAMPEDE 2-Site Survey"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-9069","authenticated-orcid":true,"given":"Omolara","family":"Fatiregun","sequence":"first","affiliation":[{"name":"Department of Radiology and Clinical Oncology, Lagos State University College of Medicine, Ikeja, Nigeria"},{"name":"Department of Clinical Oncology, Lagos State University Teaching Hospital, Ikeja, Nigeria"},{"name":"Institute of Health Management, Policy and Evaluation, Dana Lana School of Public Health, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-0492","authenticated-orcid":true,"given":"Nwamaka","family":"Lasebikan","sequence":"additional","affiliation":[{"name":"Research Department, National Institute for Cancer Research and Treatment, FCT Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-1180","authenticated-orcid":true,"given":"Onyeanunam","family":"Ekeke","sequence":"additional","affiliation":[{"name":"Urology Division, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliyu","family":"Malami","sequence":"additional","affiliation":[{"name":"Research Department, National Institute for Cancer Research and Treatment, FCT Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4431-7777","authenticated-orcid":true,"given":"Ali","family":"Gombe","sequence":"additional","affiliation":[{"name":"Research Department, National Institute for Cancer Research and Treatment, FCT Abuja, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-7116","authenticated-orcid":true,"given":"Anthonia","family":"Sowunmi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Lagos University Teaching Hospital, Idi-Araba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Temitope","family":"Olatunji-Agunbiade","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Lagos State University Teaching Hospital, Ikeja, Nigeria"},{"name":"Department of Radiotherapy, Lagos University Teaching Hospital, Idi-Araba, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-8503","authenticated-orcid":true,"given":"Basit","family":"Balogun","sequence":"additional","affiliation":[{"name":"Cancer Explore Foundation, Lagos, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boluwatife","family":"Borisade","sequence":"additional","affiliation":[{"name":"Cancer Explore Foundation, Lagos, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7537-2031","authenticated-orcid":true,"given":"Adewuyi","family":"Sunday","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Lagos University Teaching Hospital, Idi-Araba, Nigeria"},{"name":"Department of Radiotherapy and Oncology Ahmadu Bello University Teaching Hospital, Zaria, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2636-7041","authenticated-orcid":true,"given":"Ian","family":"Tannock","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Canada"},{"name":"University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-8204","authenticated-orcid":true,"given":"Nicholas","family":"James","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom"},{"name":"Department of Radiotherapy, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588"},{"key":"e_1_3_4_4_2","unstructured":"Statistics at a glance 2022 top 5 most frequent cancers number of new cases. IARC Globocan 2022"},{"key":"e_1_3_4_5_2","first-page":"451","volume-title":"Clinical Trials","author":"Parmar MKB","year":"2017","unstructured":"Parmar MKB, Sydes MR, Cafferty FH, et al: Testing many treatments within a single protocol over 10 years at MRC clinical trials unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials. Thousand Oaks, CA: SAGE Publications Ltd, 2017, pp 451-461"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.07.009"},{"key":"e_1_3_4_9_2","unstructured":"Stampede-2 trial: Stampede 2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer. 2025. http:\/\/stampede2trial.org"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001653"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00148-1"},{"key":"e_1_3_4_12_2","volume-title":"STAMPEDE2: Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) and Androgen Receptor Signaling Inhibitors (ARSI) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd multi-arm multi-stage Randomised Controlled Trial (STAMPEDE2)","author":"MRC Clinical Trials Unit at UCL","year":"2024","unstructured":"MRC Clinical Trials Unit at UCL. STAMPEDE2: Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) and Androgen Receptor Signaling Inhibitors (ARSI) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd multi-arm multi-stage Randomised Controlled Trial (STAMPEDE2). London, United Kingdom: University College London, 2024. https:\/\/www.mrcctu.ucl.ac.uk\/studies\/all-studies\/s\/stampede2\/ (2024)"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.18043\/ncm.75.4.270"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.4103\/1115-1474.121099"},{"key":"e_1_3_4_16_2","article-title":"Emerging use of public-private partnerships in public radiotherapy facilities in Nigeria","author":"Anakwenze Akinfenwa CP","unstructured":"Anakwenze Akinfenwa CP, Ibraheem A, Nwankwo K, et al: Emerging use of public-private partnerships in public radiotherapy facilities in Nigeria. JCO Glob Oncol 10.1200\/GO.21.00066","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2023.1592"},{"key":"e_1_3_4_18_2","volume-title":"Nigerian Institute for Cancer Research & Treatment (NICRAT): National Strategic Cancer Control Plan-Nigeria 2023-2027","unstructured":"Nigerian Institute for Cancer Research & Treatment (NICRAT): National Strategic Cancer Control Plan-Nigeria 2023-2027. Federal Ministry of Health, NICRAT (in press)"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:59:35Z","timestamp":1776283175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/GO-25-00232"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00232","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500232"}}